Recently, JAK2 inhibitor was reported to exert therapeutic effects by interfering with numerous pro-inflammatory cytokines via inhibition of the JAK2/STAT3 signaling pathway in COVID-19 patients (La Rosée et al., 2020). The gene discussed is JAK2; the disease is COVID-19.